The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
 
Sandra Van Schaeybroeck
No Relationships to Disclose
 
Christian D. Rolfo
No Relationships to Disclose
 
Elena Élez
No Relationships to Disclose
 
Stephen Kelly
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jennifer Houlden
No Relationships to Disclose
 
Linda Collins
No Relationships to Disclose
 
Sharon Love
No Relationships to Disclose
 
Thierry Andre
Honoraria - Amgen; Bayer; Merck Serono; Roche Pharma AG
Consulting or Advisory Role - Bayer; Lilly; Roche Pharma AG
Speakers' Bureau - Roche Pharma AG
 
Mark Lawler
No Relationships to Disclose
 
Federica Di Nicolantonio
No Relationships to Disclose
 
Margaret Grayson
No Relationships to Disclose
 
Vlad Calin Popovici
No Relationships to Disclose
 
Alberto Bardelli
Stock and Other Ownership Interests - Horizon Discovery
Consulting or Advisory Role - Biocartis; Horizon Discovery; Trovagene
 
Pierre Laurent-Puig
Leadership - IntegraGen
Honoraria - Amgen; Boehringer Ingelheim; Merck Serono
 
Manuel Salto-Tellez
No Relationships to Disclose
 
Tim Maughan
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Marc Peeters
No Relationships to Disclose
 
Richard H. Wilson
Consulting or Advisory Role - Merck; Sanofi
 
Mark R. Middleton
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Immunocore; Merck; Roche Pharma AG
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline; Immunocore; MedImmune; Merck; Pfizer; Roche Pharma AG; Vertex
Travel, Accommodations, Expenses - Merck; Roche Pharma AG